Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
about
Laquinimod therapy in multiple sclerosis: a comprehensive reviewQuetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisCo-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor CellsDimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.The future of multiple sclerosis treatments.Oral available agents in the treatment of RRMS.Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells.
P2860
Q28086844-E8543C4D-BF63-453E-A964-DE2D5789CB17Q30656233-98170493-70D2-4969-927B-BE179DB9C09DQ35659134-BA7FCE5C-E8A7-4B0A-9780-5F0D5C1CC795Q35826151-03A7940B-7731-4108-B2FE-D5B0E46968BAQ36290946-611670E3-2ACC-4FFD-BC79-DCEE03B674EEQ38195521-F4F3DA1C-89CD-4BBE-AC48-9FF02EE6926AQ38808485-4D078DE9-4515-4884-8FAB-43F523C6D4C8Q42049844-2F887DC7-65C2-4CE5-8485-5F1D75EC21FCQ47932285-FAB8F07D-77D4-4244-8787-D250BADC62C5
P2860
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Oral available agents in the t ...... erview of merits and culprits.
@ast
Oral available agents in the t ...... erview of merits and culprits.
@en
type
label
Oral available agents in the t ...... erview of merits and culprits.
@ast
Oral available agents in the t ...... erview of merits and culprits.
@en
prefLabel
Oral available agents in the t ...... erview of merits and culprits.
@ast
Oral available agents in the t ...... erview of merits and culprits.
@en
P2860
P356
P1476
Oral available agents in the t ...... erview of merits and culprits.
@en
P2093
Gisa Ellrichmann
P2860
P356
10.2147/DHPS.S28822
P407
P577
2013-02-26T00:00:00Z